Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real world retreatment study of Voxilaprevir/Velpatasvir/ Sofosbuvir in Patients with Chronic Hepatitis C Virus Infection

Trial Profile

Real world retreatment study of Voxilaprevir/Velpatasvir/ Sofosbuvir in Patients with Chronic Hepatitis C Virus Infection

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Dec 2018

At a glance

  • Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Dec 2018 New trial record
    • 13 Nov 2018 Results (N=54, as of 9 Feb, 2017) assessing retreatment with Voxilaprevir/Velpatasvir/ Sofosbuvir presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top